You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

15 Results
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Soft Tissue, 
Uterine
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2023
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
DOXOrubicin,
ifosfamide,
mesna
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2021
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Soft Tissue, 
Uterine
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Adjuvant
Drugs Used:
gemcitabine,
DOCEtaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2017
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Drugs Used:
DOCEtaxel,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2016
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
raltitrexed,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Sarcoma, 
Wilm's Tumour
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
vinCRIStine,
DACTINomycin,
DOXOrubicin,
cyclophosphamide,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
dacarbazine,
DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
DOCEtaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dostarlimab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    olaparib - For the maintenance treatment of BRCA-mutated, high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024

Pages